Opinion

Video

Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents

Author(s):

Frederick Locke, MD

Fred Locke, MD, provides an overview of transplant eligibility for patients with large B-cell lymphoma, highlighting second line strategies with CAR T-cell therapy and bispecific antibodies.

Related Videos
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Eytan M. Stein, MD
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Acute Myeloid Leukemia
December 8th 2024

Oral Revumenib-Based Combo Produces Responses in R/R AML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Blinatumomab Plus Chemo in Standard-Risk Pediatric B-ALL
December 7th 2024

Blinatumomab Plus Chemo Increases DFS Rates in Standard-Risk Pediatric B-ALL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Elias Jabbour, MD, a professor in the Department of Leukemia, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center in Houston
December 6th 2024

ALL Treatment Paradigm Displays Significant Gains as NCCN Guidelines Evolve

TERN-701 Generates Responses in R/R CML
December 4th 2024

TERN-701 Decreases BCR-ABL Levels, Generates Molecular Responses in R/R CML